BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28911356)

  • 1. High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland.
    Adams LV; Mahlalela N; Talbot EA; Pasipamire M; Ginindza S; Calnan M; Haumba S
    Int J Tuberc Lung Dis; 2017 Oct; 21(10):1127-1132. PubMed ID: 28911356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini.
    Grande SW; Adams LV; Maseko TSB; Talbot EA; deGijsel D; Mikal J; Simelane ZZ; Achili A; Mkhontfo M; Haumba SM
    PLoS One; 2020; 15(5):e0232841. PubMed ID: 32469990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.
    Maharaj B; Gengiah TN; Yende-Zuma N; Gengiah S; Naidoo A; Naidoo K
    Int J Tuberc Lung Dis; 2017 May; 21(5):537-543. PubMed ID: 28399969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
    Thindwa D; MacPherson P; Choko AT; Khundi M; Sambakunsi R; Ngwira LG; Kalua T; Webb EL; Corbett EL
    Int J Tuberc Lung Dis; 2018 Mar; 22(3):273-279. PubMed ID: 29471904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
    Assebe LF; Reda HL; Wubeneh AD; Lerebo WT; Lambert SM
    BMC Public Health; 2015 Apr; 15():346. PubMed ID: 25886730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.
    Moh R; Badjé A; N'takpé JB; Kouamé GM; Gabillard D; Ouassa T; Ouattara E; Le Carrou J; Bohoussou F; Messou E; Eholié S; Anglaret X; Danel C
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1237-1244. PubMed ID: 29297443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
    Costenaro P; Massavon W; Lundin R; Nabachwa SM; Fregonese F; Morelli E; Alowo A; Nannyonga Musoke M; Namisi CP; Kizito S; Bilardi D; Mazza A; Cotton MF; Giaquinto C; Penazzato M
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):e1-8. PubMed ID: 26761275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
    Kyaw NTT; Kumar AMV; Kyaw KWY; Satyanarayana S; Magee MJ; Min AC; Moe J; Aung ZZ; Aung TK; Oo MM; Soe KT; Oo HN; Aung ST; Harries AD
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):322-330. PubMed ID: 30871663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
    Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
    BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study.
    Mueller Y; Mpala Q; Kerschberger B; Rusch B; Mchunu G; Mazibuko S; Bonnet M
    Medicine (Baltimore); 2017 Sep; 96(35):e7740. PubMed ID: 28858089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    Nabity SA; Gunde LJ; Surie D; Shiraishi RW; Kirking HL; Maida A; Auld AF; Odo M; Jahn A; Nyirenda RK; Oeltmann JE
    PLoS One; 2021; 16(4):e0248115. PubMed ID: 33793577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
    Semu M; Fenta TG; Medhin G; Assefa D
    BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.
    Tiam A; Machekano R; Gounder CR; Maama-Maime LB; Ntene-Sealiete K; Sahu M; Isavwa A; Oyebanji O; Ahimbisibwe A; Mokone M; Barnes GL; Chaisson RE; Guay L; Kassaye S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):e5-e11. PubMed ID: 25118796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.
    Ayele HT; van Mourik MS; Bonten MJ
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1342-1347. PubMed ID: 27725045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.